Publications
Original Articles
A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast Cancer
Clinical Trials
2025
Authors:
William R Gwin III, Lupe G Salazar, James Y Dai, Doreen Higgins, Andrew L Coveler, Jennifer S Childs, Rosie Blancas, Yushe Dang, and Mary L Disis
Journal:
Vaccines
Volume:
13
Page:
117
Review Articles
Vaccines for cancer interception in familial adenomatous polyposis
2025
Authors:
David E Johnson and Mary L Disis
Journal:
Frontiers in Immunology
Volume:
16
Page:
Original Article
Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer
Clinical Trials
2024
Authors:
John B Liao, Nikita S Jejurikar, Katie M Hitchcock-Bernhardt, William R Gwin, Jessica L Reichow, Yushe Dang, Jennifer S Childs, Andrew L Coveler, Ron E Swensen, Barbara A Goff, Mary L Disis, Lupe G Salazar
Journal:
Gynecologic Oncology
Volume:
191
Page:
74-79
Original Articles
Magnitude of antigen-specific T-cell immunity the month after completing vaccination series predicts the development of long-term persistence of antitumor immune response
Cancer Vaccines
2024
Authors:
John B Liao, James Y Dai, Jessica L Reichow, Jong-Baeck Lim, Katie M Hitchcock-Bernhardt, Sasha E Stanton, Lupe G Salazar, Theodore A Gooley, Mary L Disis
Journal:
Journal for Immunotherapy of Cancer
Volume:
12(11)
Page:
e010251
Original Article
A Phase I/II Trial of HER2 Vaccine-Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2-Overexpressing Breast Cancer
Clinical Trials
2023
Authors:
Disis ML, Dang Y, Coveler AL, Childs JS, Higgins DM, Liu Y, Zhou J, Mackay S, Salazar LG
Journal:
Clinical Cancer Research
Volume:
29(17)
Page:
3362-3371
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
2023
Authors:
Disis, ML, Adams, SF, Bajpai, J, Butler, MO, Curiel, T, Dodt, SA, Doherty, L, Emens, LA, Friedman, CF, Gatti-Mays, M, Geller, MA, Jazaeri, A, John, VS, Kurnit, KC, Liao, JB, Mahdi, H, Mills, A, Zsiros, E, and Odunsi, K
Journal:
Journal for Immunotherapy of Cancer
Volume:
11
Page:
Original Article
Anti-tumor activity of a T-helper 1 multiantigen vaccine in a murine model of prostate cancer
Cancer Vaccines
2022
Authors:
Cecil, D.L., Curtis, B, Gad, E., Gormley, M, Timms, A.E., Corulli, L., Bos, R., Damle, R.N., Sepulveda, M.A., and Disis, M.L.
Journal:
Scientific Reports
Volume:
12
Page:
13618
Original Article
COX-2 Inhibitors Decrease Expression of PD-L1 in Colon Tumors and Increase the Influx of Type I Tumor-infiltrating Lymphocytes
Cancer Vaccines
2022
Authors:
Cecil DL, Gad EA, Corulli LR, Drovetto N, Lubet RA, Disis ML
Journal:
Cancer Prevention Research
Volume:
15(4)
Page:
225-231
Original Article
Unexpected Liver and Kidney Pathology in C57BL/6J Mice Fed a High-fat Diet and Given Azoxymethane to Induce Colon Cancer
Cancer Vaccines
2022
Authors:
Waggie, KS, Corulli, LR, Cecil, D, Rodmaker, ER, Walsh, C, and Disis, ML
Journal:
Comparative Medicine
Volume:
72(5)
Page:
330-335
Original Article
Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer
Clinical Trials
2022
Authors:
Disis, ML, Guthrie, KA, Liu, Y, Coveler, AL, Higgins, DM, Childs, JS, Dang, Y, and Salazar, LG
Journal:
JAMA Oncology
Volume:
9(1)
Page:
71-78